BioScrip Inc (BIOS) Receives a Buy from Barrington


Barrington analyst Michael Petusky maintained a Buy rating on BioScrip Inc (NASDAQ: BIOS) today and set a price target of $4. The company’s shares opened today at $2.79.

Petusky commented:

“We continue to model further improvement in gross margin over the next couple of years.”

According to TipRanks.com, Petusky is a 4-star analyst with an average return of 16.0% and a 59.8% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.

Currently, the analyst consensus on BioScrip Inc is a Moderate Buy with an average price target of $3.75.

See today’s analyst top recommended stocks >>

Based on BioScrip Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $15.14 million. In comparison, last year the company had a GAAP net loss of $29.2 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioScrip, Inc. engages in the provision of home infusion and home care management solutions. It partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts